海正药业(600267) - 2024 Q1 - 季度财报
HISUNHISUN(SH:600267)2024-04-29 11:39

Financial Performance - Net profit attributable to shareholders for Q1 2024 was CNY 248,531,288.09, representing an increase of 6.99% year-on-year [13]. - Operating revenue for Q1 2024 was CNY 2,726,615,253.70, down 11.00% compared to the same period last year [13]. - Basic earnings per share for Q1 2024 were CNY 0.21, reflecting a growth of 10.53% compared to the previous year [13]. - Diluted earnings per share for Q1 2024 were CNY 0.21, an increase of 23.53% year-on-year [13]. - Operating profit for Q1 2024 was CNY 272,881,031.20, compared to CNY 295,762,745.82 in Q1 2023, reflecting a decline of 7.7% [35]. - The net profit for Q1 2024 was approximately ¥246.35 million, an increase from ¥241.53 million in Q1 2023, representing a growth of about 2.5% [45]. - The total revenue for Q1 2024 was ¥270.59 million, compared to ¥295.65 million in Q1 2023, indicating a decrease of approximately 8.5% [45]. - The basic earnings per share for Q1 2024 was ¥0.21, up from ¥0.19 in Q1 2023, marking an increase of approximately 10.5% [45]. Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 17,430,133,954.21, a decrease of 1.04% compared to the end of the previous year [7]. - Total liabilities amounted to approximately ¥9.14 billion, a decrease from ¥9.26 billion in the previous period, reflecting a reduction of about 1.2% [23]. - The company's total assets were reported at approximately ¥17.43 billion, compared to ¥17.61 billion in the previous period, representing a decrease of about 1.0% [23]. - The total equity attributable to shareholders at the end of Q1 2024 was CNY 8,044,565,413.40, a decrease of 0.71% from the end of the previous year [7]. - The total equity attributable to shareholders was approximately ¥8.04 billion, down from ¥8.10 billion, indicating a decline of about 0.7% [23]. - The total current liabilities were reported at approximately ¥7.21 billion, compared to ¥6.58 billion, indicating an increase of about 9.7% [23]. - The total non-current liabilities decreased to approximately ¥1.93 billion from ¥2.68 billion, indicating a reduction of about 28.0% [23]. Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY 315,089,920.00, an increase of 3.49% year-on-year [13]. - Cash flow from operating activities in Q1 2024 was CNY 315,089,920.00, slightly up from CNY 304,464,171.32 in Q1 2023 [38]. - The company's cash outflow for operating activities in Q1 2024 was CNY 2,581,859,593.57, compared to CNY 2,992,356,769.67 in Q1 2023, indicating a reduction of 13.8% [38]. - The cash flow from investment activities showed a net outflow of ¥44.94 million in Q1 2024, compared to a net outflow of ¥130.00 million in Q1 2023, reflecting an improvement in cash management [41]. - The cash flow from financing activities resulted in a net outflow of ¥271.80 million in Q1 2024, contrasting with a net inflow of ¥47.58 million in Q1 2023, indicating a shift in financing strategy [41]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,413 [16]. - The number of shares held by the top ten shareholders included Zhejiang Haizheng Group with 320,783,590 shares, representing a significant portion of the total equity [23]. - The company plans to implement an employee stock ownership plan using shares repurchased through market transactions, which accounted for 2.18% of total shares [23]. Other Financial Metrics - The weighted average return on equity for Q1 2024 was 3.10%, an increase of 0.27 percentage points compared to the previous year [13]. - Non-recurring gains and losses included a government subsidy of CNY 13,474,807.23 and a fair value change gain of CNY 109,980,090.46 from financial assets [8]. - Long-term borrowings rose to approximately ¥1.28 billion, an increase from ¥1.12 billion, reflecting a growth of about 14.3% [23]. - The company's retained earnings increased to approximately ¥2.23 billion, up from ¥1.98 billion, showing a growth of about 12.5% [23]. - The company's cash and cash equivalents were CNY 1,568,730,864.92 as of March 31, 2024, slightly down from CNY 1,586,627,072.09 at the end of 2023 [30]. - Inventory as of March 31, 2024, was CNY 1,830,044,519.42, a decrease from CNY 1,956,874,088.91 at the end of 2023, reflecting a reduction of 6.4% [30]. - The company reported a decrease in other comprehensive income, with a net amount of -¥717,310.31 in Q1 2024 compared to -¥1,388,894.91 in Q1 2023, indicating a reduction in losses from other comprehensive income [45]. - The company raised ¥2.12 billion through financing activities in Q1 2024, compared to ¥1.40 billion in Q1 2023, showing an increase in capital acquisition efforts [41]. - The company experienced a foreign exchange impact of ¥892,114.61 on cash and cash equivalents in Q1 2024, contrasting with a negative impact of -¥827,928.55 in Q1 2023, indicating improved currency stability [41]. - The company reported a decrease in operating expenses, with non-operating expenses of ¥2.56 million in Q1 2024 compared to ¥166,327.00 in Q1 2023, reflecting better cost control measures [45].